| SEKISUI MEDICAL CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120064553 | BLOOD COAGULATION TIME PROLONGING AGENT - Provided is a reagent, which prolongs a blood coagulation time sufficiently and enhances an optical change, thereby enabling a correct and high-sensitive blood coagulability test. The present invention provides a blood coagulation time prolonging agent, including, as an active ingredient, a guanidine compound represented by the following formula (1) or an acid addition salt thereof (in the formula, R | 03-15-2012 |
| 20120040476 | IMMUNOASSAY REAGENT FOR KL-6 ASSAY - The present invention aims to provide an assay reagent and an assay for accurately measuring KL-6, in particular, an assay reagent and an assay for accurately measuring KL-6 in samples containing a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor. KL-6 in samples that contain a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor can be accurately measured using an immunoassay reagent comprising a solution at a pH of 4.0 to 5.5 containing a rheumatoid factor interference inhibitor and a solution of an insoluble carrier on which anti-KL-6 antibodies are immobilized. | 02-16-2012 |
| 20120015388 | Diluent for Preparing Analytical Sample - The ionic strength of a diluent for preparing an analytical sample is set to be 0.06 to 0.16. The analytical sample prepared by using the diluent having the ionic strength within this range can be subjected to both for analyzing a first object in a test sample by electrode method and for analyzing a second object in the test sample by liquid chromatography method, and high-precision measurement can be attained. The analytical sample is especially useful for preparing a sample for measurement used both for measuring glucose concentration in a blood sample by enzyme electrode method and for measuring glycohemoglobin concentration in the blood sample by liquid chromatography method. | 01-19-2012 |
| 20110318765 | METHOD FOR PRE-TREATING SAMPLE CONTAINING GLYCATED HEMOGLOBIN - There are provided a pre-treatment technique for a glycated hemoglobin-containing sample, which is a simple and convenient treatment, is free from problems in storage stability and environmental aspects, and is capable of exposing an epitope sufficiently in a short time; and an method for an immunological assay of glycated hemoglobin using this technique. | 12-29-2011 |
| 20110311989 | ANTIBODY TO N-TERMINAL REGION OF HEMOGLOBIN BETA-CHAIN - Provided is a general-purpose technique capable of measuring the HbA1c content, which is comparable to the IFCC reference method. An antibody which reacts with a peptide or a protein having an amino acid sequence of VHLTPE (SEQ ID NO: 1) at the N-terminus in which the N-terminal valine is not modified, but does not react with a peptide or a protein in which the N-terminal valine of the relevant polypeptide or protein is modified. | 12-22-2011 |
| 20110250653 | L-SUCCINYLAMINOACYLASE AND PROCESS FOR PRODUCING L-AMINO ACID USING IT - The present invention provides a L-succinylacylase consisting of: (a) a protein coded by a gene consisting of a nucleic acid sequence shown in SEQ ID No: 1; (b) a protein consisting of an amino acid sequence shown in SEQ ID No: 2; (c) a protein coded by a polynucleotide which hybridizes under a stringent condition with a nucleic acid sequence which is complementary to the nucleic acid sequence shown in SEQ ID No: 1 and having an L-succinylaminoacylase activity; or (d) a protein which consists of an amino acid sequence where one or several amino acid(s) is/are substituted, deleted, inserted and/or added in the protein consisting of the amino acid sequence shown in SEQ ID No: 2 and has an L-succinylaminoacylase activity. This enzyme is able to produce a sterically bulky unnatural amino acid such as L-tert-leucine etc. which is useful as an intermediate for pharmaceuticals. | 10-13-2011 |
| 20110244530 | L-SUCCINYLAMINOACYLASE AND PROCESS FOR PRODUCING L-AMINO ACID USING IT - The present invention provides an L-aminoacylase which is able to produce L-tert-leucine being useful as an intermediate for pharmaceuticals. | 10-06-2011 |
| 20110236996 | METHOD FOR MEASURING CYSTATIN C IN HUMAN BODY FLUID - There is provided a particle-enhanced immunoassay method for cystatin C in a human body fluid, which has higher specificity and is easily automatable at low cost as compared with conventional assay methods that use large amounts of polyclonal antibodies having low specificity or monoclonal antibodies having high specificity but having poor agglutinability. | 09-29-2011 |
| 20110186511 | LIQUID CHROMATOGRAPHY APPARATUS AND LIQUID CHROMATOGRAPHY - A liquid chromatography apparatus is provided with a sample preparation unit, a column that separates components of a sample, an eluent supplier that includes a feeder for supplying eluents to the column, a flow path directional valve capable of introducing fixed amounts of the sample and the eluents to the column, an analyzer for analyzing a test solution composed of the sample components separated by the column and one of the eluents, and a controller, wherein the eluent supplier supplies the eluents to the flow path directional valve in an unmixed state. As a result of employing this configuration, analysis time is shortened and eluent consumption is reduced. | 08-04-2011 |
| 20110177610 | NOVEL MARKER FOR ARTERIOSCLEROTIC DISEASE - Disclosed is a novel marker for an arteriosclerotic disease. Also disclosed is a method for evaluating the presence or level of an arteriosclerotic disease in a mammal, or a method for evaluating the prophylactic or therapeutic effect on an arteriosclerotic disease in a mammal, which is characterized by detecting a soluble LR11 in a sample collected from the mammal. | 07-21-2011 |
| 20110152573 | PROCESS FOR PRODUCING N-PROTECTED AMINO ACID - The present invention relates to a method for producing N-protected amino acid. Specifically, the present invention provides a method in which a protecting group is introduced to the amino group of an amino acid in a reaction under alkaline condition, and the N-protected amino acid thus generated is then separated from the reaction solution as crystals, without undergoing an extraction step or a concentration step. The present inventors have completed the invention based on the finding that desirable crystals of N-protected amino acids may be obtained without extraction, concentration or recrystallization steps between the initial generation of the N-protected amino acid molecules and the subsequent separation of the crystals, by first adding an water-soluble organic solvent and optionally water to the reaction solution (alkaline) containing the N-protected amino acid, and then neutralizing the solution by an acid. | 06-23-2011 |
| 20110129862 | METHOD FOR DETERMINING CAUSE OF THE PROLONGATION OF BLOOD COAGULATION TIME - Provided is a method of accurately and easily determining a cause of the prolongation of blood coagulation time. | 06-02-2011 |
| 20110104825 | METHOD FOR ENHANCING SENSITIVITY OR METHOD FOR AVOIDING INFLUENCE OF HEMOGLOBIN IN IMMUNOLOGICAL MEASUREMENT - To provide a technique for enhancing measurement sensitivity or a technique for avoiding a hemoglobin influence in an immunoassay method. | 05-05-2011 |
| 20110104709 | POROUS SOLID PHASE FOR BINDING ASSAY, AND BINDING ASSAY METHOD USING THE SAME - A porous solid phase for binding assay that enables a test sample such as whole blood to be analyzed promptly, conveniently, accurately, and inexpensively without requiring a pretreatment, and a binding assay method using said porous solid phase are disclosed. At least one surfactant is incorporated into the porous solid phase for binding assay prior to addition of a test sample, the at least one surfactant being selected from the group consisting of (A) a sugar-containing surfactant that comprises a compound shown by a general formula (I), (B) a sugar-containing surfactant that comprises a sucrose fatty acid ester wherein the constituent fatty acid has 5 to 14 carbon atoms, and (C) a steroid surfactant. | 05-05-2011 |
| 20110098475 | FLUORESCENT PROBES - A fluorescent probe which is represented by the following formula (wherein R | 04-28-2011 |
| 20110091993 | METHOD FOR QUANTIFICATION OF SOLUBLE LR11 - Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid. | 04-21-2011 |
| 20110033944 | METHOD FOR MEASURING HYPOCHLORITE ION - A method for measuring hypochlorite ion, which comprises the steps of: | 02-10-2011 |
| 20100330685 | DIAMINORHODAMINE DERIVATIVE - A compound represented by the following formula (I) or (II): | 12-30-2010 |
| 20100330600 | HIGH-MOLECULAR-WEIGHT ADIPONECTIN MEASUREMENT METHOD - Provided is a method of separating and measuring highly active HMW adiponectin in adiponectin multimers. A method of measuring high-molecular-weight adiponectin in a sample, wherein adiponectin multimers are separated by use of a protease and measured immunologically, the method comprising reacting a sample containing adiponectin multimers with chymotrypsin. | 12-30-2010 |
| 20100310597 | ANTI-OFLOXACIN MONOCLONAL ANTIBODY AND IMMUNOASSAY OF OFLOXACIN USING THE SAME - A method that accurately and conveniently detects a compound shown by the formula (I) in a human sample is disclosed. An antibody that reacts with the compound shown by the formula (I), but does not cross-react with the N-oxide metabolite and the desmethyl levofloxacin metabolite of the compound shown by the formula (I) is prepared using an antigen produced by binding bovine serum albumin to the compound shown by the formula (I) through the 6-position carboxyl group. | 12-09-2010 |
| 20100113786 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL - Disclosed is a method for highly efficiently obtaining an optically active alcohol from a carbonyl compound highly enantioselectively. Also disclosed is a ligand used in such a method. Specifically, an optically active alcohol is obtained by reacting a carbonyl compound and an organozinc compound by using a ligand (L) shown below. | 05-06-2010 |
| 20100047834 | METHOD FOR STABILIZING ALPHA-THROMBIN IN THROMBIN-CONTAINING SOLUTION - To provide a method for stabilizing unstable α-thrombin in a thrombin-containing solution, a solution containing stabilized α-thrombin, and a liquid fibrinogen assay reagent containing the solution. The method for stabilizing α-thrombin in a thrombin-containing solution, which includes adjusting the percentage of α-thrombin to 70% or more with respect to the amount of total thrombin in the thrombin-containing solution. | 02-25-2010 |
| 20100029010 | Diaminorhodamine Derivative - A compound represented by the following formula (I) or (II): | 02-04-2010 |
| 20090263915 | AGGLUTINATION INHIBITION ASSAY METHOD AND REAGENT - Provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, which can be used for measuring a ligand in a sample at high sensitivity in a wide range from the low-concentration range to the high-concentration range and have good reproducibility of measurement. Specifically, provided are an agglutination-inhibition assay and a reagent for agglutination-inhibition assay, in which used are an insoluble carrier particle carrying a ligand, a specific receptor in the free-form and an insoluble carrier particle carrying a specific receptor which binds to a different site on the ligand than the receptor in the free-form. | 10-22-2009 |
| 20080249321 | Fluorescent Probes - A fluorescent probe which is represented by the following formula (wherein R | 10-09-2008 |
